Zevin Drug Interactions

Aciclovir may interact with the following as follows: Foscarnet: May enhance the nephrotoxic effect of aciclovir.
Mycophenolate: Aciclovir may increase the serum concentration of mycophenolate.
Mycophenolate may increase the serum concentration of aciclovir.
Talimogene laherparepvec: Antiherpetic antivirals may diminish the therapeutic effect of talomogene laherparepvec.
Tenofovir Products: Aciclovir may increase the serum concentration of tenofovir products. Tenofovir products may increase the serum concentration of aciclovir.
Varicella Virus Vaccine: Aciclovir may diminish the therapeutic effect of varicella virus vaccine.
Zoster Vaccine: Aciclovir may diminish the therapeutic effect of zoster vaccine.
Antifungal Agents: Amphotericin B has been shown to potentiate the antiviral effect of aciclovir against pseudorabies virus in vitro when both drugs are added to the culture medium. Ketoconazole and aciclovir have shown dose-dependent, synergistic, antiviral activity against herpes simplex virus type 1 and 2 (HSV-1 and 2) in in vitro replication studies. The clinical importance of these interactions has not been established, and additional study is necessary to determine potential antiviral synergy between these antifungal agents and aciclovir.
Probenecid: Concomitant administration of probenecid and aciclovir has reportedly increased the mean plasma half-life and area under the plasma concentration-time curve (AUC) and decreased urinary excretion and renal clearance of aciclovir. In one study following oral administration of a 1 g dose of probenecid 1 hour prior to a 1 hour IV infusion of aciclovir 5 mg/kg, the half-life and AUC for aciclovir increased by 18% and 40%, respectively, and urinary excretion and renal clearance of aciclovir decrease by 13% and 32%, respectively. This interaction may result from competitive inhibition of the renal secretion of aciclovir by probenecid.
Interferon: IV aciclovir should be used with caution in patients receiving interferon. In vitro, when aciclovir and interferon are both added cultures of herpes simplex virus type 1 (HSV-1), the drugs have an additive or synergistic antiviral effect; however, the clinical importance of this interaction is not known.
Methotrexate: IV aciclovir should be used with caution in patients receiving intrathecal methotrexate.
Zidovudine: Aciclovir has been used concomitantly with zidovudine in some patients with human immunodeficiency virus (HIV) infections without evidence of increased toxicity; however, neurotoxicity (profound drowsiness and lethargy), which recurred on rechallenge, has been reported in at least one patient with acquired immunodeficiency syndrome (AIDS) during concomitant therapy with the drugs. Neurotoxicity was evident within 30-60 days after initiation of IV aciclovir therapy, persisted with some improvement when aciclovir was administered orally, and resolved following discontinuance of aciclovir in this patient.